CDB-4124
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
WikiDoc Resources for CDB-4124 |
Articles |
---|
Most recent articles on CDB-4124 |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on CDB-4124 at Clinical Trials.gov Clinical Trials on CDB-4124 at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on CDB-4124
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Directions to Hospitals Treating CDB-4124 Risk calculators and risk factors for CDB-4124
|
Healthcare Provider Resources |
Causes & Risk Factors for CDB-4124 |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
CDB-4124 (Proellex™, Progenta™) is a selective progesterone receptor modulator.[1]
References
- ↑ Attardi BJ, Burgenson J, Hild SA, Reel JR (2004). "In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone". J Steroid Biochem Mol Biol. 88 (3): 277–88. doi:10.1016/j.jsbmb.2003.12.004. PMID 15120421.